Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Habitual activity associates with lower fasting and greater glucose-induced GLP-1 response in men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gluco-metabolic effects of oral and intravenous alcohol administration in men

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. GIP-induced vasodilation in human adipose tissue involves capillary recruitment

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Long-term outcome following laser therapy of benign cystic-solid thyroid nodules

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Semen quality in hypogonadal acromegalic patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hippocampal Volume, Cognitive Functions, Depression, Anxiety, and Quality of Life in Patients With Cushing Syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objectives: Recent large cohort studies suggest an association between high plasma prolactin and cardiovascular mortality. The objective of this systematic review was to systematically assess the effect of reducing prolactin with dopamine agonist on established cardiovascular risk factors in patients with prolactinomas.

Design: Bibliographical search was done until February 2019 searching the following databases: PubMed, EMBASE, WHO and LILAC. Eligible studies had to include participants with verified prolactinomas where metabolic variables were assessed before and after at least 2 weeks treatment with dopamine agonists.

Methods: Baseline data and outcomes were independently collected by two investigators. The study was registered with PROSPERO (registration number CRD42016046525).

Results: Fourteen observational studies enrolling 387 participants were included. The pooled standardized mean difference of the primary outcome revealed a reduction of BMI and weight of -0.21 (95% CI -0.37 to -0.05; P = 0.01; I2 = 71%), after treatment. Subgroup analysis suggested that the reduction of weight was primarily driven by studies with high prolactin levels at baseline (P = 0.04). Secondary outcomes suggested a small decrease in waist circumference, a small-to-moderate decrease in triglycerides, fasting glucose levels, HOMA-IR, HbA1c and hsCRP, and a moderate decrease in LDL, total cholesterol and insulin.

Conclusion: This systematic review suggests a reduction of weight as well as an improved lipid profile and glucose tolerance after treatment with dopamine agonist in patients with prolactinomas. These data are based on low-quality evidence.

Original languageEnglish
JournalEndocrine Connections
Volume8
Issue number10
Pages (from-to)1395-1404
Number of pages10
ISSN2049-3614
DOIs
Publication statusPublished - Oct 2019

ID: 59233321